课题基金 / 基金详情

Evaluation of the anticancer activity of a new autophagy-inhibitory drug

Evaluation of the anticancer activity of a new autophagy-inhibitory drug
新型自噬抑制药物的抗癌活性评价
批准号:
194925
负责人:
Roberge Michel
金额:
$10.42万
依托单位国家:
加拿大
项目类别:
Operating Grants
财政年份:
2009
资助国家:
加拿大
项目状态:
已结题
起止时间:
2009-10-01 至 2010-10-01

项目摘要

项目成果

Roberge Michel的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Several cancer drugs elicit a protective response called autophagy (self-eating) that enables cancer cells to survive exposure to the drug. It is anticipated that autophagy inhibitors will increase the efficacy of these drugs but few chemical inhibitors o
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Mutation-targeted gene and pharmacological therapies for dystrophic and junctional Epidermolysis Bullosa
  • 批准号:
    367021
  • 项目类别:
    Operating Grants
  • 资助金额:
    $22.25万
  • 财政年份:
    2017
  • 负责人:
    Roberge Michel
  • 依托单位:
Preclinical evaluation of a gentamicin analog as a treatment for genetic diseases and cancer due to a premature termination codon.
  • 批准号:
    335020
  • 项目类别:
    Operating Grants
  • 资助金额:
    $10.93万
  • 财政年份:
    2015
  • 负责人:
    Roberge Michel
  • 依托单位:
Preclinical Development of a novel M2 Channel Inhibitor for the Treatment and Prevention of Influenza
  • 批准号:
    293922
  • 项目类别:
    Operating Grants
  • 资助金额:
    $11.66万
  • 财政年份:
    2013
  • 负责人:
    Roberge Michel
  • 依托单位:
海外基金